Information Provided By:
Fly News Breaks for March 14, 2019
UNH, MYGN
Mar 14, 2019 | 05:13 EDT
After hosting investor meetings with management, Piper Jaffray analyst William Quirk believes Myriad Genetics (MGN) is "on the cusp of several positive news events." Management is optimistic that they could get a draft local coverage determinations for expanded GeneSight coverage by Medicare, Quirk tells investors in a research note. He expects visibility on this by late March. Further, the analyst believes Counsyl's April 1 in-network status with UnitedHealth (UNH) could lead to $6M-$7M upside to his current Q4 estimates. Quirk reiterates an Overweight rating on Myriad Genetics with a $47 price target.
News For MYGN;UNH From the Last 2 Days
UNH
Mar 28, 2024 | 15:22 EDT
What has Wall Street been buzzing about this week? Here are the top 5 Bu-y calls and the top 5 Sell calls made by Wall Street’s best analysts during the week of March 25-28. Find all top-rated... To see the rest of the story go to thefly.com. See Story Here
UNH
Mar 28, 2024 | 06:51 EDT
BofA downgraded Molina Healthcare (MOH) to Underperform from Neutral with a $439 price target. The firm, which is concerned that Molina and the Medicaid industry more broadly are likely to face rate pressure after a period of elevated margins, sees a less attractive risk/reward for Molina compared to other insurers the firm covers, the analyst tells investors. Molina is now trading roughly at parity with the firm's top pick in the space, UnitedHealth (UNH), compared to a 22% discount that had been seen over the last five years, helping to underscore the firm's view that "sentiment for Medicaid is nearing a top just at a time when Medicare is reaching a bottom," the analyst added.